Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vobramitamab Duocarmazine · MGC-018

Antibody-drug conjugate · Cytotoxic, directed at B7-H3 (CD276) · developed by MacroGenics

Phase 2 Most advanced trial
MGNX Developer
2 Registered trials

What is Vobramitamab Duocarmazine?

Vobramitamab duocarmazine is an antibody-drug conjugate in which a humanized IgG1 antibody binds B7-H3 (CD276) on tumor cells and is internalized. A cleavable valine-citrulline linker releases the duocarmycin payload, which alkylates DNA and induces cell death. It is being studied in small-cell lung cancer, prostate cancer, head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer and anal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MGC-018
Drug type
Antibody-drug conjugate
Targets
B7-H3 (CD276)
Mechanism
Cytotoxic, directed at B7-H3 (CD276)
Pathways
DNA alkylation, apoptosis
Therapy area
Oncology
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
2ZK3D69DQJ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06227546 Phase 2 Extensive-stage Small-cell Lung Cancer Active not recruiting MGNX
NCT05551117 Phase 2 Castration-Resistant Prostatic Cancer Terminated MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Extensive-stage Small-cell Lung CancerAnal CancerAnal NeoplasmAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic CancerAndrogen-Resistant Prostatic CancerCarcinoma, Squamous Cell of Head and NeckCastration-Resistant Prostatic CancerHead and Neck Squamous Cell CarcinomaHormone Refractory Prostatic CancerLaryngeal Squamous Cell CarcinomaMalignant MelanomaMelanomaNon-small Cell Carcinoma

Other drugs acting on CD276

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind Vobramitamab Duocarmazine

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.